Clinical Trial Update: A Trial of Pembrolizumab for Refractory Atypical and Anaplastic Meningioma [Phase 2]

View source ↗

Summary

Phase 2 trial of pembrolizumab for refractory atypical and anaplastic meningioma has terminated; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaplastic Meningioma
• Atypical Meningioma
• Hemangiopericytoma

Drugs mentioned

• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Rabin Medical Center | Conditions: Atypical Meningioma, Anaplastic Meningioma | Phase 2 | Status: TERMINATED | Results posted: 2025-01-22